About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/21/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/21/2021.

Digoxin Induced Dissolution of CTC Clusters

Clinicaltrials.gov identifier NCT03928210

Recruitment Status Recruiting

First Posted April 26, 2019

Last update posted September 18, 2020

Study Description

Brief summary:

This single arm therapeutic exploratory study of digoxin in patients with advanced or metastatic breast cancer investigates whether cardiac glycosides are able to disrupt CTC clusters in breast cancer patients.

  • Condition or Disease:Breast Cancer
    Circulating Tumor Cells (CTCs)
  • Intervention/Treatment: Drug: Digoxin
  • Phase: Early Phase 1
Detailed Description

Circulating tumor cells (CTCs) are considered to be precursors of metastasis in various cancer types and are found in the blood of cancer patients as single CTCs and CTC clusters, with the latter featuring a higher ability to seed metastasis. CTC cluster share several properties that commonly feature stem cell biology which drive metastases formation. Preclinical data shows that CTC clusters can be disaggregated into single cells by the treatment with cardiac glycosides such as digoxin. This single arm therapeutic exploratory study of digoxin in patients with advanced or metastatic breast cancer investigates whether cardiac glycosides are able to disrupt CTC clusters in breast cancer patients. Patients with advanced or metastatic breast cancer in whom CTC clusters could be identified will receive an individualized daily maintenance dose of digoxin adapted to their kidney function. Blood samples for analyses of digoxin serum level and mean CTC cluster size will be drawn at specified time points.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 9 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Effect of Digoxin on Clusters of Circulating Tumor Cells (CTCs) in Breast Cancer Patients
  • Actual Study Start Date: July 2020
  • Estimated Primary Completion Date: May 2021
  • Estimated Study Completion Date: June 2021
Arms and interventions
Arm Intervention/treatment
Experimental: Digoxin
Drug: Digoxin
Patients will receive a daily maintenance dose of digoxin. The daily dose of digoxin will be calculated according to the renal function and the target serum digoxin concentration and applied in an adjusted regimen based on the availability of 0.125 mg and 0.25 mg pills in the morning (before 10 am). Blood samples for analyses of mean CTC cluster size will be drawn at screening, on day 0 (2 hrs after first oral intake), on day 3 and on day 7. Depending on the digoxin serum level maintenance therapy with digoxin will be continued up to 3 weeks if the digoxin serum level on day 7 or day 14 is below 0.70 ng/ml. For the third week of maintenance therapy individual dose adjustments will be carried out as needed.
Outcome Measures
  • Primary Outcome Measures: 1. Change in mean CTC cluster size (in ng/ml) [ Time Frame: Blood samples drawn at Screening, on day 0 (2 hours after first oral intake of digoxin), on day 3, on day 7, on day 10, on day 14, on day 17 and on day 21 after first oral intake of digoxin ]
    mean CTC cluster size (in patients with a digoxin serum level above 0.7 ng/ml) after treatment will be compared to mean CTC-cluster size before treatment
  • Secondary Outcome Measures: 1. Change in mean CTC cluster number [ Time Frame: Blood samples drawn at Screening, on day 0 (2 hours after first oral intake of digoxin), on day 3, on day 7, on day 10, on day 14, on day 17 and on day 21 after first oral intake of digoxin ]
    number of CTC-clusters before and after treatment will be compared
  • 2. Average time to dissolution of CTC Clusters (in days) [ Time Frame: Blood samples drawn at Screening, on day 0 (2 hours after first oral intake of digoxin), on day 3, on day 7, on day 10, on day 14, on day 17 and on day 21 after first oral intake of digoxin ]
    average time to dissolution of CTC clusters
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Informed Consent as documented by signature

- Diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or
metastatic disease not amenable to resection, radiation therapy or systemic therapy
with curative intent

- Adequate organ and marrow function

Exclusion Criteria:

- Patients on treatment with digoxin or digitoxin

- Patients with atrial fibrillation or atrial flutter

- Ventricular Fibrillation or ventricular tachycardia,

- Atrioventricular heart block 2nd or 3rd degree, sick sinus syndrome or sinus
bradycardia,

- Wolff-Parkinson-White Syndrome

- Hypokalemia, hypercalcemia, hypomagnesemia, hypoxia,

- Hypertrophic cardiomyopathy, aortic aneurysm

- Simultaneous intravenous application of calcium salts

- Known hypersensitivity to Digoxin, other cardiac glycosides or included compounds

- Known drug interactions of ongoing cancer therapy with digoxin

- Women who are pregnant or breast feeding,

- Intention to become pregnant during the course of the study,

- Lack of safe contraception

- Other clinically significant concomitant disease states (e.g., renal failure, hepatic
dysfunction, cardiovascular disease)

- Known or suspected non-compliance, drug or alcohol abuse

- Inability to follow the procedures of the study, e.g. due to language problems,
psychological disorders, dementia, etc. of the participant

- Participation in another study with investigational drug within the 30 days preceding
and during the present study,

- Previous enrolment into the current study,

- Enrolment of the investigator, his/her family members, employees and other dependent
persons

Contacts and Locations
Contacts

Contact: Christian Kurzeder, PD Dr. med +41 61 26 52525 christian.kurzeder@usb.ch

Contact: Marcus Vetter, PD Dr. med +41 61 26 52525 marcus.vetter@usb.ch

Locations

Switzerland
Breast Cancer Center, University Hospital Basel
Basel

Sponsors and Collaborators

University Hospital, Basel, Switzerland

Investigators

Principal Investigator: Christian Kurzeder, PD Dr. med Breast Cancer Center, University Hospital Basel

More Information
  • Responsible Party: University Hospital, Basel, Switzerland
  • ClinicalTrials.gov Identifier: NCT03928210 History of Changes
  • Other Study ID Numbers: 2019-00673; sp19Kurzeder
  • First Posted: April 26, 2019 Key Record Dates
  • Last Update Posted: September 18, 2020
  • Last Verified: September 2020
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by University Hospital, Basel, Switzerland: cluster of circulating tumor cells (CTCs)
    cardiac glycosides
    digoxin
  • Additional relevant MeSH terms: Breast Neoplasms Neoplastic Cells, Circulating